A structured technical collaboration program connecting biopharmaceutical process development scientists with next-generation purification technologies.

PROGRAM CHAIR

Professor Stefano Menegatti

NC STATE UNIVERSITY | CHROMAGENIX

Shaping GMP-ready purification technologies around your process constraint

If your team is working through unresolved purification constraints in mRNA, lentiviral vectors, viral vector impurity control or recombinant protein HCP clearance, NAVIGATE provides a structured route to discuss the problem and help define what a useful solution would need to prove.

NAVIGATE connects development teams directly to our tunable synthetic ligand development capabilities and expertise to overcome downstream processing bottlenecks. 

Share your challenge, help refine product specifications, define your performance requirements and shape your roadmap to a GMP-ready manufacturing solution. 

Through structured Product Focus Sessions and Product Focus Groups, participants help define what future GMP-ready purification tools must demonstrate in real workflows: recovery, impurity clearance, functional preservation, scalability, cleaning compatibility, analytical requirements and process fit. 

From Collaboration to GMP-Ready Product

HOW IT WORKS

Focus Areas

Why participate?

Early technical visibility

Review emerging technology direction before release.

Direct product input

Help define the performance thresholds, process conditions, analytical readouts and GMP-readiness expectations that would make a future product useful.

Scientist-led discussion

Engage with ChromaGenix technical teams on the process problem, not a generic sales pitch.

Potential evaluation pathway

Where there is technical fit, discussion may progress toward deeper data review, Product Focus Group participation, prototype evaluation or collaboration.

FAQs

Who should join from our team?

The strongest sessions usually include process development, DSP, analytical, MSAT or CMC stakeholders who understand the current workflow and the evidence required for technical adoption and can work directly with our Applications and R&D scientists.

What information do we need to provide?

Useful inputs include molecule or modality, workflow position, feedstream context, impurity burden, current purification approach, analytical readouts, recovery targets, scalability constraints and where the process currently creates the most burden.

What is the onboarding process?

Typically we conduct a brief technical qualification session with your choice of either meeting with one of our scientists or completing a questionnaire.

This is to ensure our offering is a good fit for your process challenge. Once assessed we will recommend a framework for ongoing collaboration to support your needs. This could be active development, testing, technical collaboration or a further meeting with a wider team if necessary. 

What data is available?

Public content may include approved development summaries and non-confidential development data. Deeper datasets, prototype details, experimental context, applications services and process-specific discussion may require CDA-covered engagement.

Are these technologies available to order?

NAVIGATE products are in emerging or advanced development-stages unless otherwise stated. The purpose is to make our tunable development pipeline accessible to early adopters experiencing real process constraints using current commercially-available technologies, in order to provide a GMP-ready, scalable solution. 

Is this a product evaluation?

Not always. NAVIGATE is our way to connect with process development scientists to ensure we're providing unique, practical solutions to solve currently unmet needs in downstream processing. 

Where the technology, maturity and process need align, the discussion may progress toward prototype evaluation or ongoing collaboration.

Evaluating AAV capture? Discover AvXcelTM

Our serotype-agnostic, alkaline-stable AAV affinity resin with flexible elution properties for higher recovery and preserved viral activity.

Put your downstream challenge into focus

Join NAVIGATE as an early adopter. Test new resins with your own feedstock, access pre-commercial data, and be first to know when products launch. 

Complete the form and a member of our team will be in touch shortly.

Form Title or Action Step

Put the form here instead of this text box.

Chris Major

CEO

Chris is responsible for identifying investment opportunities, assessing strategic fit within the portfolio, and supporting growth-related operational initiatives. A serial entrepreneur with over 20 years of bioprocessing experience, he has deep expertise across upstream and downstream technologies. Prior to BioProcess360, he founded and led the Purolite Bioprocessing division, growing it from zero revenue in 2015 to $80M in six years. The business was acquired by Ecolab (NYSE: ECL) in 2021 for $3.7BN. Earlier, Chris helped pioneer single-use technology at WAVE Bioreactors, later acquired by GE Healthcare (now Cytiva), and held senior roles at GE and Merck Millipore. He holds an MSc in Biotechnology and attended Harvard Business School. Outside work, Chris enjoys biking, paddleboarding, live music, and spending time with his two daughters.